Loading clinical trials...
Loading clinical trials...
This is a non-interventional, prospective, post authorization safety study. Patients with gMG who are expected to start treatment with efgartigimod at enrolment or are within their first cycle of efga...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
argenx
NCT06312644 · Ultomiris-exposed Pregnant/ Postpartum, Pregnancy, and more
NCT06754020 · Myasthenia Gravis
NCT07089121 · Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV), and more
NCT07470151 · System Lupus Erythematosus(SLE), Scleroderma, and more
NCT07247279 · Rare Diseases, Generalized Myasthenia Gravis (gMG)
UCSF Medical Center - Helen Diller Family Comprehensive Cancer Center - Brain Tumor Center,
San Francisco, California
SFM Clinical Research, LLC
Boca Raton, Florida
University of Florida College of Medicine Jacksonville
Jacksonville Beach, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions